Menu Search
Equities

Lantheus Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0L8:DUS

Lantheus Holdings Inc

Actions
  • Price (EUR)54.44
  • Today's Change-0.76 / -1.38%
  • Shares traded20.00
  • 1 Year change-38.07%
  • Beta-0.0743
Data delayed at least 15 minutes, as of Feb 06 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.

  • Revenue in USD (TTM)1.53bn
  • Net income in USD167.68m
  • Incorporated2007
  • Employees808.00
  • Location
    Lantheus Holdings Inc331 Treble Cove RoadNORTH BILLERICA 01862United StatesUSA
  • Phone+1 (978) 671-8001
  • Fax+1 (302) 636-5454
  • Websitehttps://www.lantheus.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.